drug that could affect IGF-I levels such as oral contraceptives or hormone replacement therapy. The subjects visited the hospital after an overnight fast and their medical history was taken. Height, weight and waist circumference were measured and blood was withdrawn from the ante-cubital vein. Fasting plasma glucose, serum ALT, total cholesterol and creatinine were measured by routine methods. Blood samples for the determination of IGF-I were centrifuged at room temperature for 10 minutes at 3,000 rpm. The sera obtained were stored on ice and placed into freezers at -20 °C on the same day. They were studied in the laboratory of the Mitsubishi Chemical Medience Co., Tokyo, Japan.
Serum IGF-I concentrations were determined by commercially available immunoradiometric assay (IRMA) kit (IGF-I assay "Daiichi"; TFB, Inc., Japan) after dissociation of IGF-I from IGF-binding proteins by non-extraction methods [17] . One hundred randomly selected serum samples were also measured by another commercially available IRMA kit (Somatomedin-C-II "Siemens"; Mitsubishi Chemical Medience Co., Japan [18, 19] ). Both assays have been calibrated against the WHO International Reference Reagent 87/518. The intra-and inter-assay coefficients of variation were less than 5% and 8%, respectively, at analyte levels of 400 and 50 ng/mL.
To evaluate the efficacy of IGF-I in screening for patients with severe GHD, we obtained anonymized pretreatment IGF-I data of subjects with severe GHD from the database of the Foundation for Growth Science, Japan [20] and from clinical studies of GH therapy for adult GHD [21] [22] [23] [24] . In total, 747 children (523 boys and 224 girls) aged two months to 18 years and 67 adults (34 males and 33 females) aged 18 to 24 years with childhood-onset severe GHD diagnosed according to the criteria by the Hypothalamo-Pituitary Dysfunction Study Group of the Japanese Ministry of Health, Labor and Welfare [25] with recombinant human GH measurements were available for this purpose.
The Ethical Committee of the National Hospital Organization Kyoto Medical Center and of the SogoRinsho-Yakuri Institute approved the clinical study [15] . Written informed consent was obtained from all of the newly recruited participants.
Statistical Analyses
Construction of the centile curves was performed with the LMS Chart Maker Pro version 2.3 software when serum IGF-I levels rapidly decline. Children with all degrees of mild to severe GHD are considered candidates for GH replacement, whereas in adulthood, only patients with severe GHD are currently indicated for GH therapy. Therefore, re-evaluation of the diagnosis at the transition period, when the major pediatric goal of treatment, i.e. the adult height, has been reached, is vital. Measurement of serum IGF-I concentration is recommended for screening for patients with severe GHD [13, 14] . In Japan, GH therapy for adults with severe GHD was approved by the Ministry of Health, Labor and Welfare in 2006. From these points of view, there is an urgent need to establish normative IGF-I references that can be utilized throughout one's life.
In this cross-sectional study, we re-analyzed serum IGF-I levels of a previously defined cohort of children [12] and measured serum IGF-I levels in an additional 1,120 healthy adult subjects [15] in order to establish normative data for the Japanese population from birth to senescence.
Subjects and Methods
A total of 586 children (293 boys and 293 girls) of the defined cohort were re-analyzed using the raw data described previously [12] . We considered that these data were applicable for the present study, because nutritional status of Japanese children did not change so much between 1996 and 2011 judging from the national nutrition survey [16] , and auxological standards of Japanese children (i.e. height, weight and body mass index) are based on the national survey in 2000. A total of 1,120 participants over 18 years old were recruited by Sogo-Rinsho-Yakuri Institute [15] . We excluded subjects from medical histories who had pituitary disorders, thyroid disease, gigantism or acromegaly, short stature, diabetes mellitus, liver disease (liver cirrhosis in particular), renal disease, and severe cardiac disease, those who were pregnant or lactating and others who had suffered from an acute illness within 4 weeks. Moreover, those whose serum creatinine was elevated to more than 1.8 mg/dL, whose fasting blood glucose concentration was more than 116 mg/dL, or whose ALT level was 3-fold that of the upper normal values were also excluded. And obese or extremely thin subjects with a body mass index above 30 kg/m 2 or below 17 kg/m 2 , respectively, were also excluded from this study; cut-off values were based on the WHO definition of obesity and mild thinness. No subjects were using any studies of GH therapy for adult GHD patients [20] [21] [22] [23] [24] . The average pretreatment IGF-1 SDS in children with severe GHD was -2.1±1.6 (males, -1.7±1.0: females, -3.0±2.2) and that in childhood-onset adult GHD was -4.9±2.5 (males, -3.3±1.3: females, -6.6±2.4). The percentages of patients showing less than -2 SD were 45.5% (males, 37.1%: females, 65.2%) and 94.0% (males, 88.2%: females, 100%) in childhood and adult patients, respectively.
Discussion
In the present study, we established the age-and gender-specific ranges for serum IGF-1 levels measured by IRMA from birth to senescence in a sample of 1,685 healthy Japanese subjects. The median IGF-1 levels increased slowly in prepubertal children from 70-150 ng/mL with a further steep increase during puberty to approximately 350 ng/mL. Peaks of serum IGF-I levels were observed at 13 years of age in program (The Institute of Child Health, London), which fit smooth centile curves to the reference data of serum IGF-I using the LMS method. This method summarizes percentiles at each age based on the power of the agespecific Box-Cox power transformations that are used to normalize data [26] . The final curves of the percentiles were produced by three curves representing skewness (L curve), the median (M curve) and coefficient of variation (S curve). The L, M, S values were smoothed for each age and gender using cubic spline curves [27] . Two subjects whose serum creatinine was elevated to more than 1.8 mg/dL or whose ALT level was 3-fold that of the upper normal values were excluded. We excluded 11 children and 8 adults as extreme outliers from the analysis by the LMS method since their IGF-I values were above or below the median ± 2.81 standard deviation (SD); therefore, the final analysis set consisted of a total of 1,685 cases (845 males and 840 females). Table 1 shows the numbers and gender of subjects in each age group. Since the serum IGF-I concentration did not show a normal distribution, peaked at puberty and declined with age after puberty in both males and females, we adopted the LMS method to analyze these data. The calculated median ± 2SDs of serum IGF-1 and L, M, S values by age for males and females are shown in Table 2a and b, respectively. Scatter plots and smoothing curves of +2SD, +SD, median, -SD and -2SD of serum IGF-I for males and females are depicted in Fig. 1a and b, respectively. There was a gender difference in IGF-I levels: females had higher values than males during childhood and adolescence, and males had higher values than females after 35-years of age.
Results
The two commercially available IRMAs showed very similar values. The coefficient of correlation of the two assays was as high as 0.9864: the conversion equation by the Deming correlation method is expressed as (Daiichi) = 18.03 + 0.822 (Siemens), as shown in Fig. 2 .
The SD score (Z-score) of serum IGF-I measurement (y value) was calculated from the L, M and S curves, using values appropriate for the age and gender, by the following equation: Z= [(y/M) L -1] / (L×S), and if L=0, Z=ln (y/M)/S. With this equation, we calculated SD scores (SDS) of pretreatment IGF-1 levels in children with severe GHD whose data were obtained from the Foundation for Growth Science, Japan and from clinical Values were calculated by the LMS method with lms Chart Maker. National standardized reference of IGF-I Values were calculated by the LMS method with lms Chart Maker.
Fig. 1
Scatter plots and smoothing curves of +2SD, +SD, Median, -SD, -2SD of serum IGF-I values in Japanese male (a) and female (b) subjects girls and 14 years of age in boys, compatible with the results of previous studies [9, 10, [28] [29] [30] [31] [32] . These gender differences were in line with the observation that girls experience peak height velocity earlier than boys. After puberty, observed serum IGF-I levels decreased rapidly, reaching a plateau in early adulthood. A subsequent continuous fall in circulating IGF-I levels was apparent throughout adulthood to a mean of 100 ng/ mL at the age of 70 years. The decline was steeper in women, who had higher levels initially, but had lower levels than men by the age of 35 years. These gender differences have also been reported in other studies [33, 34] , and might result from the diminished estrogen levels with aging in women [34] , as estrogens play a major and positive role in regulating the GH/IGF-I axis in both genders [35] . Accordingly, we believe that new Japanese references have been successfully produced and can be adequately used from birth to senescence. The newly established reference values were constructed by the LMS method with all subjects together, which we believe is one of the most widely applicable approaches for age-related reference intervals [36] . There were three reasons for our adopting the LMS method to construct the reference charts, although other investigators have used other statistical methods such as the polynominal equation model [29] and quantile regression model [33] . The first reason was that with the LMS method, we could easily produce convincing centile curves even when the skewness of data changed with age. In the present study, indeed, the serum IGF-I measurements were not normally distributed, and the skewness of the distribution varied with age. The reference values in the charts constructed by the polynomial equation model are offset from the conditional mean dependent on the global SD of the initially transformed variables because that model assumes that the reference distribution follows a normal distribution without age-variation in skewness. From this point of view, we thought that the LMS method was superior to the polynomial equation model in the present study. The second reason was that the resulting L, M and S curves contained the information needed to draw any kind of centile curve, and to convert measurements into an exact SDS. With reference curves constructed by a quantile regression model, we cannot calculate the exact SDS with any measurement. When we utilize these references to analyze many measurements, SDS is very useful for both clinical management and research purposes. The third reason was that in the LMS method maximum penalized likelihood was used to estimate the age-related curves for each of L, M, and S by natural cubic splines, which indicated that subjective grouping step was removed and the curve fitting across age was controlled directly by the values of equivalent degrees of freedom for three smoothing parameters [36] . Actually, adopting the LMS method with all subjects together which included adequate number of subjects for smoothing centile curves, we could represent the rapid decline from puberty to early adulthood smoothly in the newly established centile curves, compared with those established in the previous studies [10, [28] [29] [30] [31] , although numbers of subjects around 16 years of age were very small. On the other hand, centile curves constructed by the polynominal equation model or quantile regression model would be undersmoothed, and a bump or a dip would be observed, which reflected the sampling error with small numbers of subjects around 16 years of age. Based on these factors, we decided to adopt the LMS method to generate percentile curves of serum IGF-I levels.
We also found the utility of IGF-I in screening for severe GHD patients, especially in the transition period aged 18 to 24 years. The mean pretreatment IGF-I SDS in patients with severe GHD obtained from the clinical studies for childhood-onset adult GHD was -4.9±2.5 (male, -3.3±1.3: female, -6.6±2.4), and its sensitivity in detecting patients less than -2 SD was 94.0% (male, 88.2%: female, 100%). Moreover, serum IGF-I levels of all subjects except one male were less than 200 ng/mL, which is the cut-off level for screening severe GHD patients recommended in the Japanese guideline for the management of GH-treated adolescents in transition to adult care [14] . These results let us conclude that newly established references for serum IGF-I levels were useful for screening severe GHD patients in the transition period. On the other hand, the utility of IGF-I for severe GHD in childhood was limited, as the percentage of these patients showing less than -2 SDS was 45.5% (male, 37.1%: female, 65.2%). These results may be explained by the fact that IGF-I appears to be regulated by multiple factors and a variable percentage of severe GHD patients have completely normal results [37] . However, the mean SDS of serum IGF-I levels in children with severe GHD was -2.1±1.6 (boy, -1.7±1.0: girl, -3.0±2.2), which was low enough to consider GHD as a differential diagnosis. The combination of serum IGF-I level with auxological information would provide ample information for diagnosis. Taken together, we considered that these references are useful for screening for patients with severe GHD even in childhood.
In conclusion, the present study established ageand gender-specific normative data of IGF-I for the Japanese population and showed the utility of this reference for screening patients with severe GHD before GH replacement therapy. These reference intervals of serum IGF-I levels could be widely used in clinical practice and would assist in calculating patients' SDS.
